Investigation of the Cultural Adaptation, Validity, and Reliability of the Turkish Version of the CAP Questionnaire

Investigation of the Cultural Adaptation, Validity, and Reliability of the Turkish Version of the Central Aspects of Pain (CAP) Questionnaire

The "CAP questionnaire," developed by modifying the CAP-Knee questionnaire to assess potential nociplastic pain features in painful musculoskeletal disorders, has been described. The "CAP questionnaire" is used in people with musculoskeletal pain and diagnostic subgroups of osteoarthritis, back pain, and fibromyalgia. There is no Turkish version of the CAP questionnaire. This study aims to investigate the cultural adaptation, validity, and reliability of the Turkish version of the "CAP questionnaire."

Study Overview

• Status: Recruiting
• Conditions: Osteoarthritis; Back Pain; Fibromyalgia
• Intervention / Treatment: Other: Questionnaire study

Detailed Description

Chronic pain is a symptom shared by many musculoskeletal conditions, even when disease management is optimized. Musculoskeletal pathologies are reported to be an essential therapeutic target in pain management. However, these pathologies often do not adequately explain the pain or the reason for its persistence.

Central sensitization is the increased sensitivity of Central Nervous System (CNS) neurons to a standard nociceptive input. Pain that increases in intensity and distribution beyond that explained by musculoskeletal pathology has been termed "nociplastic pain." Measuring these CNS aspects of pain is a prerequisite for understanding their mechanistic basis and predicting future pain and responses to treatment. Chronic pain is associated with CNS dysfunction in several areas, including depression, anxiety, pain catastrophizing, cognitive dysfunction, sleep disturbance, and fatigue. Considering the increasing importance of assessing mood-related pain (nociplastic pain) The "CAP questionnaire," developed by modifying the CAP-Knee questionnaire to assess potential nociplastic pain features in painful musculoskeletal disorders, has been described.

• Study Type: Observational
• Enrollment (Estimated): 300

Contacts and Locations

• Study Contact: Name: Orkun Tüfekçi, PT, PhD (c); Phone Number: 5319502648; Email: orkuntf@gmail.com

Study Locations

• Turkey
  • Altındağ
    • Ankara, Altındağ, Turkey, 06100
      • Recruiting
      • Hacettepe University
      • Contact: Orkun Tüfekçi, PT, PhD(c); Phone Number: +90 312 305 25 25; Email: orkuntf@gmail.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Probability Sample

Study Population

The study population will consist of individuals who come to the university hospital for routine controls.

Description

Inclusion Criteria:

• People with musculoskeletal pain and in diagnoses with OA, back pain, or FM
• Above 18 years of age
• Informed consent of the participant

Exclusion Criteria:

• Diagnosis of uncontrolled/other clinically significant diseases (chronic obstructive pulmonary disease, congestive heart failure, endocrine system diseases, neurological, psychological diseases, etc.)
• Pregnant women

Study Plan

How is the study designed?

Number of groups / cohorts

3

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Individuals with osteoarthritis	Other: Questionnaire study; Questionnaire application; Other Names: CAP questionnaire
Individuals with back pain	Other: Questionnaire study; Questionnaire application; Other Names: CAP questionnaire
Individuals with fibromyalgia	Other: Questionnaire study; Questionnaire application; Other Names: CAP questionnaire

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Central Aspects of Pain Questionnaire (CAP)	The CAP questionnaire consists of eight items assessing each of the eight characteristics linked to the central mechanisms of knee pain over the past week. These items assess neuropathic-like pain, fatigue, cognition, catastrophizing, anxiety, depression, sleep, and widespread pain.	Three months

Secondary Outcome Measures

Outcome Measure	Time Frame
BETY-Biopsychosocial Questionnaire	Three months
Hospital Anxiety Depression Scale (HADS)	Three months
Health Assessment Questionnaire (HAQ)	Three months
Pain Catastrophizing Scale (PCS)	Three months
Central Sensitisation Inventory (CSI)	Three months
Short-Form of McGill's Pain Questionnaire	Three months

Collaborators and Investigators

• Sponsor: Hacettepe University

Study record dates

Study Major Dates

• Study Start (Actual): November 28, 2024
• Primary Completion (Estimated): November 28, 2027
• Study Completion (Estimated): November 28, 2027

Study Registration Dates

• First Submitted: February 9, 2025
• First Submitted That Met QC Criteria: February 9, 2025
• First Posted (Actual): March 25, 2025

Study Record Updates

• Last Update Posted (Actual): March 25, 2025
• Last Update Submitted That Met QC Criteria: February 9, 2025
• Last Verified: November 1, 2024

More Information

Terms related to this study

• Keywords: osteoarthritis; pain; back pain; fibromyalgia; central sensitization; nociplastic pain
• Additional Relevant MeSH Terms: Pain; Neurologic Manifestations; Musculoskeletal Diseases; Nervous System Diseases; Muscular Diseases; Neuromuscular Diseases; Arthritis; Joint Diseases; Rheumatic Diseases; Back Pain; Osteoarthritis; Fibromyalgia; Myofascial Pain Syndromes
• Other Study ID Numbers: SBA 24/997

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: Will not be shared to protect the data of individuals

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No